Champix
DrugStandard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days
1mb b.d. for 70 days (full course 3 months)
Other names: varenicline tartrate, Chantix
NCT Number: NCT01141855
The Smoking Termination Opportunity for inPatients, (STOP) project is designed to capture the opportunity that is provided by admission for acute smoking related illness, to assist patients through withdrawal by use of a combination of:
* the new medication Champix with * best practice counselling * initiated in an inpatient setting
to achieve:
* sustained smoking abstinence * reduced hospital bed and health service utilisation * reduced inpatient smoking and craving prior to discharge
Looking for future studies?
Notify Me20 year–75 year
All sexes
Interventional
Phase 2 / Phase 3
Lyell McEwin Health Service, Adelaide, South Australia, Australia
A national standard in public hospitals for the management of smoking in patients admitted with smoking related acute illnesses is lacking. Where such patients have continued to smoke up until the time of admission, it can be assumed that "primary" prevention has failed.
Once admitted, there is a vastly under-utilised opportunity, by use of a structured and systematic approach, to intervene with a secondary prevention attempt. This takes advantage of the synergy of:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days
1mb b.d. for 70 days (full course 3 months)
Other names: varenicline tartrate, Chantix
Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
Other names: Quitline counselling service
Time frame: one year
Continued smoking abstinence is defined as: less than or equal to no more than 5 cigarettes smoked during the period of 2 weeks to 12 months post enrollment.
Time frame: one year
Hospital casemix/DRG data will be collected for the 5 years prior to enrollment and one year post enrollment. This will be supplemented by SA Department of Health data and PBS/MBS data sets of study completion, to monitor admissions at other hospitals and GP visits.
Time frame: from 2 weeks to 3 months post enrollment
Defined as no cigarettes for the previous 7 days
Time frame: one year
Reduced health care costs with greater economic value will be relative to other health interventions. Four seperate economic models will be built for vascular diseases: cardiovascular, cerebrovascular and peripheral vascular diseases and airways diseases: asthma and/or chronic obstructive pulmonary disease. Each model will compare outcomes and costs for varenicline and counselling compared to counselling alone, and will incorporate epidemiological data on natural disease progression of smokers and previous smokers from the four disease profiles split by gender if indicated.
Time frame: baseline to end of inpatient stay
Craving scales will be used to assess levels during inpatient stay (pre and post intervention delivery)
Time frame: From baseline to end of inpatient stay
Measured by self-report and observation by hospital and study staff prior to discharge.
The Queen Elizabeth Hospital
Other
Effectiveness of Inpatient Initiated Varenicline Tartrate for Smoking Cessation, for Smoking Related Illnesses.
Acronym: STOP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03259360
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT04560868
Behavior, Behavior, Smoking
Seattle, Washington, United States
View Trial DetailsNCT01691105
Behavior, Chemically-Induced Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT00507728
Behavior, Chemically-Induced Disorders
Houston, Texas, United States
View Trial Details